Corient Private Wealth LLC Trims Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Corient Private Wealth LLC lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 59.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 125,450 shares of the company's stock after selling 180,904 shares during the period. Corient Private Wealth LLC owned about 0.15% of IDEXX Laboratories worth $51,866,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Insight Wealth Strategies LLC increased its stake in IDEXX Laboratories by 230.5% in the fourth quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company's stock valued at $4,174,000 after purchasing an additional 7,041 shares during the period. Larson Financial Group LLC increased its position in IDEXX Laboratories by 17,238.5% in the 3rd quarter. Larson Financial Group LLC now owns 2,254 shares of the company's stock valued at $1,139,000 after acquiring an additional 2,241 shares during the period. Quest Partners LLC raised its stake in IDEXX Laboratories by 4,059.4% during the 3rd quarter. Quest Partners LLC now owns 2,870 shares of the company's stock valued at $1,450,000 after acquiring an additional 2,801 shares during the last quarter. Ontario Teachers Pension Plan Board acquired a new stake in IDEXX Laboratories during the 3rd quarter worth approximately $749,000. Finally, Geode Capital Management LLC grew its stake in shares of IDEXX Laboratories by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,259,537 shares of the company's stock valued at $1,138,732,000 after purchasing an additional 40,349 shares during the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

IDEXX Laboratories Price Performance

Shares of IDXX traded up $0.37 on Friday, reaching $420.99. The stock had a trading volume of 706,610 shares, compared to its average volume of 550,561. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $548.88. The firm has a market capitalization of $34.24 billion, a PE ratio of 39.46, a PEG ratio of 3.41 and a beta of 1.39. The firm has a 50-day moving average of $437.30 and a 200 day moving average of $445.53. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.

Insiders Place Their Bets

In other news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares of the company's stock, valued at $3,781,645.28. The trade was a 54.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Piper Sandler increased their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Leerink Partnrs raised shares of IDEXX Laboratories to a "strong-buy" rating in a report on Monday, December 2nd. StockNews.com cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Saturday, March 15th. Barclays lifted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Finally, Morgan Stanley cut their target price on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, IDEXX Laboratories has a consensus rating of "Moderate Buy" and an average target price of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.